Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Faisal Hasan

Interventional Cardiology Chicago, IL Medical Doctor

NPI 1710922505 CMS profile 304224

1725 W Harrison St Ste 1159, Chicago, IL 60612

Open in the dashboard

General payments

$6,333

62 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Faisal Hasan of Chicago, IL is reported in the CMS Open Payments database as having received $6,333 across 62 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 45th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $288 2
2024 General $1,886 21
2023 General $1,189 12
2022 General $2,955 26
2019 General $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Faisal Hasan
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Faisal Hasan were reported at $288. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Faisal Hasan Interventional Cardiology median Middle half National median
2019 $15 $1,097 $329–$3,048 $163
2020 $0 $473 $161–$1,480 $114
2021 $0 $677 $233–$1,827 $132
2022 $2,955 $978 $333–$2,724 $149
2023 $1,189 $1,136 $382–$2,986 $160
2024 $1,886 $1,181 $395–$3,326 $164
2025 $288 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,998 29 payments
  2. Edwards Lifesciences Corporation $1,549 16 payments
  3. Siemens Medical Solutions USA, Inc. $1,032 8 payments
  4. Terumo Medical Corporation $253 3 payments
  5. HeartFlow, Inc. $232 2 payments
  6. Boston Scientific Corporation $114 1 payment
  7. Mentor Worldwide LLC $101 1 payment
  8. Philips Electronics North America Corporation $39 1 payment
  9. W. L. Gore & Associates, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,483 21 payments
  2. Food and Beverage $2,850 41 payments
Products named General payments · program years 2019–2025
  1. Artis icono floor $664 5 payments
  2. PASCAL $513 4 payments
  3. FFRct $232 2 payments
  4. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $181 2 payments
  5. SYMPLICITY G3 $169 2 payments
  6. SAPIEN 3 Ultra RESILIA $142 1 payment
  7. MENTOR MemoryGel Resterilizable Gel Sizer $101 1 payment
  8. (BR0) Coronary Atherectomy $39 1 payment
  9. EVOQUE $37 1 payment
  10. VIABAHN Endoprosthesis with Heparin Bioactive Surface $15 1 payment
  11. Other $7 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

282

Median for Interventional Cardiology: 2,236

Drug cost

$3,899

Median for Interventional Cardiology: $380,412

Branded share of claims

13.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amlodipine-Valsartan Amlodipine Besylate/Valsartan Brand 23 $896
Metoprolol Succinate Generic 37 $664
Atorvastatin Calcium Generic 59 $489
Cilostazol Generic 21 $488
Bumetanide Generic 16 $353
Ezetimibe Generic 14 $312
Clopidogrel Clopidogrel Bisulfate Brand 16 $178
Amlodipine Besylate Generic 20 $140
Rosuvastatin Calcium Generic 25 $121
Losartan Potassium Generic 12 $103

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$59,012

Medicare's payments for the services billed

Medicare patients

221

Average age 74

Services billed

481

110 women, 111 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 62%
Diabetes 59%
Chronic kidney disease 58%
Arthritis 55%
Atrial fibrillation 46%
COPD 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

62 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record